NSW HEPATITIS INFOLINE
1800 803 990

hep C

DAAs decrease hep C deaths but double GPs needed

Hepatitis C deaths have declined by 20% in the two years since direct-acting antivirals were added to the PBS, infectious diseases physicians say. Professor Greg Dore, from the Kirby Institute, says the decline in deaths among patients with liver disease is remarkable and testament to the high uptake of the drugs.

“Around 10% of GPs have written a script for these new therapies — we’d like to potentially double that.”

www.pharmacynews.com.au/news/remarkable-results-daas-decrease-hep-c-deaths

Read more

Fewer Australians are dying from hepatitis C

The number of Australians dying from liver failure and liver cancer related to hepatitis C has dropped by 20 per cent in just two years, according to preliminary data released today by The Kirby Institute. It follows the introduction of highly effective, low-cost curative drugs to the Pharmaceutical Benefits Scheme (PBS) in 2016.

“This decline reflects the high uptake of direct-acting antiviral therapies among people with hepatitis C, particularly those with more advanced liver disease,” said Greg Dore from the Kirby Institute.

www.abc.net.au/news/health/2018-08-13/fewer-australians-dying-from-hepatitis-c

Read more

Govt intervenes to keep hep C elimination on track

NSW Health is encouraging people across the state living with hepatitis C to take advantage of new easy-to-take and highly effective medications, which can cure the illness. The medication program is part of the NSW Ministry of Health’s $4.5 million investment in 2018-19 to strengthen hepatitis C testing and treatment.

This year, Hepatitis Awareness Week is focusing on increasing treatment efforts for people who inject drugs. All people who currently inject drugs or have previously injected drugs should ask their doctor for a hepatitis C test and for hepatitis C treatment if they do have the infection.

www.theleader.com.au/story/5553811/keeping-hepatitis-c-elimination-on-track/

Read more